Inhibrx Inc (INBX)
34.05
-0.04
(-0.12%)
USD |
NASDAQ |
Apr 26, 16:00
34.05
0.00 (0.00%)
After-Hours: 18:45
Inhibrx Cash from Operations (TTM): -193.31M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -193.31M |
September 30, 2023 | -167.09M |
June 30, 2023 | -143.68M |
March 31, 2023 | -128.30M |
December 31, 2022 | -115.30M |
September 30, 2022 | -107.32M |
June 30, 2022 | -90.16M |
March 31, 2022 | -85.62M |
December 31, 2021 | -80.32M |
September 30, 2021 | -73.09M |
Date | Value |
---|---|
June 30, 2021 | -73.30M |
March 31, 2021 | -62.23M |
December 31, 2020 | -47.97M |
September 30, 2020 | -44.52M |
June 30, 2020 | -31.41M |
March 31, 2020 | -33.89M |
December 31, 2019 | -32.08M |
September 30, 2019 | -33.14M |
June 30, 2019 | -34.48M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-193.31M
Minimum
Dec 2023
-31.41M
Maximum
Jun 2020
-83.01M
Average
-73.30M
Median
Jun 2021
Cash from Operations (TTM) Benchmarks
Johnson & Johnson | 22.79B |
Gilead Sciences Inc | 8.006B |
Outlook Therapeutics Inc | -47.10M |
Axonics Inc | -2.016M |
NovaBay Pharmaceuticals Inc | -4.131M |